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Abstract 
Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease of hematological malignancy 
or bone marrow transplant patients caused by the ubiquitous environmental fungus Aspergillus 
fumigatus. Current diagnostic tests for the disease lack sensitivity as well as specificity, and culture 
of the fungus from invasive lung biopsy, considered the gold standard for IPA detection, is slow and 
often not possible in critically ill patients. In a previous study, we reported the development of a 
novel non-invasive procedure for IPA diagnosis based on antibody-guided positron emission 
tomography and magnetic resonance imaging (immunoPET/MRI) using a [64Cu]DOTA-labeled 
mouse monoclonal antibody (mAb), mJF5, specific to Aspergillus. To enable translation of the tracer 
to the clinical setting, we report here the development of a humanised version of the antibody 
(hJF5), and pre-clinical imaging of lung infection using a [64Cu]NODAGA-hJF5 tracer. The 
humanised antibody tracer shows a significant increase in in vivo biodistribution in A. fumigatus 
infected lungs compared to its radiolabeled murine counterpart [64Cu]NODAGA-mJF5. Using 
reverse genetics of the pathogen, we show that the antibody binds to the antigenic determinant 
β1,5-galactofuranose (Galf) present in a diagnostic mannoprotein antigen released by the pathogen 
during invasive growth in the lung. The absence of the epitope Galf in mammalian carbohydrates, 
coupled with the enhanced imaging capabilities of the hJF5 antibody, means that the 
[64Cu]NODAGA-hJF5 tracer developed here represents an ideal candidate for the diagnosis of IPA 
and translation to the clinical setting. 
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Introduction 
Infectious diseases caused by viruses, bacteria, 
and fungi remain a leading cause of death worldwide 
[1], with fungi responsible for an estimated 2 million 
life-threatening infections each year [2]. At present, 
there is a paucity of diagnostic tests that can 
accurately differentiate these infectious etiologies, 
resulting in the incorrect prescription of antimicrobial 
drugs and emergence of widespread resistance to 
antibiotics and antifungals [3]. Both rapid 
point-of-care tests [4] and more sophisticated 
diagnostic modalities [5] compatible with 
contemporary medical facilities are urgently needed 
to allow pathogen discrimination and implementation 
of targeted treatments [3]. Here, molecular imaging 
has huge potential to deliver accurate, non-invasive, 
and rapid detection of infectious diseases with the 
prospect of earlier diagnosis, efficient therapy and 
improved survival rates. While still in their infancy, 
highly specific antibody-guided imaging technologies 
have recently been described for the in vivo diagnosis 
of viral [6], bacterial [7] and fungal diseases [8] in 
animal models, with genuine potential for translation 
to human disease diagnosis. 
Invasive pulmonary aspergillosis (IPA) is a 
life-threatening lung disease of immunocompromised 
individuals with the majority of infections caused by 
the fungus Aspergillus fumigatus. Conservative 
estimates show that the opportunistic pathogen is 
responsible for >200,000 infections of hematological 
malignancy, hematopoietic stem cell transplant 
(HSCT) and solid organ transplant patients 
worldwide each year, with an associated mortality 
rate of between 30 and 90 % [2]. While the disease is 
typically associated with prolonged neutropenia, it is 
being increasingly reported in non-neutropenic 
patients, such as those with underlying lung diseases 
including steroid-treated chronic obstructive 
pulmonary disease (COPD), asthma, lung cancer, or 
autoimmune diseases with pulmonary involvement 
[4]. In addition, it has been estimated that chronic 
pulmonary aspergillosis (CPA) and allergic 
bronchopulmonary aspergillosis (ABPA) affect >15 
million people globally each year [2]. Taken together, 
diseases caused by Aspergillus spp. constitute a 
serious but often hidden threat to human health, 
adding to patient morbidities and hospital treatment 
costs. Arguably, much of this burden derives from the 
lack of accurate tests for disease diagnosis. 
Diagnosis of IPA is a major clinical challenge 
since manifestations of the disease (fevers and chills, 
hemoptysis, shortness of breath, chest pains, 
headaches) are non-specific, and assays that are 
presently used to detect Aspergillus cell wall 
galactomannans and fungal β-D-glucan in serum or 
bronchoalveolar lavage fluids lack either sensitivity or 
specificity [9]. High-resolution CT is increasingly used 
to identify IPA, but lung abnormalities suggestive of 
the disease such as nodules and “halo sign” can be 
caused by other angio-invasive fungal and bacterial 
pathogens or even non-infectious pathologies, and so 
are unable to differentiate IPA from other pulmonary 
diseases [9]. 
Positron emission tomography and magnetic 
resonance imaging (PET/MRI) has proven to be an 
extremely powerful tool for the diagnosis of cancer 
[5], but has yet to be fully exploited in the diagnosis of 
microbial infections [10, 11]. However, we recently 
demonstrated the enormous potential of 
antibody-guided PET/MRI (immunoPET/MRI) for 
the molecular imaging of both bacterial [7] and fungal 
[8] infections in vivo. Importantly, we showed that a 
mouse monoclonal antibody (mJF5), which 
specifically binds to a diagnostic Aspergillus 
mannoprotein antigen [12, 13], when conjugated to 
[64Cu]DOTA, can be used successfully in a 
neutropenic mouse model of IPA to image Aspergillus 
lung infections in vivo [8]. The highly specific 
[64Cu]DOTA-mJF5 tracer allows repeated imaging of 
A. fumigatus lung infections and differentiation of IPA 
from pulmonary inflammation and from infections 
caused by bacteria.  
In this study, we report the development of a 
humanized version of JF5 (hJF5), generated using 
CDR grafting, and investigate its accuracy in 
detecting A. fumigatus lung infections in vivo 
compared to the mouse antibody. We show that 
conjugation of mJF5 to [64Cu]DOTAGA or 
[64Cu]NODAGA allows specific detection of lung 
infections, while [64Cu]NODAGA-labeled hJF5 
enables additional improvements in disease detection 
compared to the mouse tracers. Furthermore, using 
reverse genetics to produce mutants of A. fumigatus 
deficient in UDP-galactopyranose mutase, a key 
enzyme in the biosynthesis of galactofuranose 
containing glycoconjugates in A. fumigatus [14-16], we 
show that the antibodies bind to the antigenic 
determinant β1,5-galactofuranose (Galf) present in the 
diagnostic mannoprotein antigen. The absence of the 
epitope Galf in mammalian carbohydrates [17], 
coupled with the improved imaging capabilities of the 
hJF5 antibody, means that the [64Cu]NODAGA-hJF5 
tracer represents an ideal candidate for the diagnosis 
of IPA in humans and translation to the clinical 
setting.  
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Material and Methods 
Design of humanised JF5 antibody 
 Full-length antibody constructs were generated 
from the sequenced variable regions of the 
Aspergillus-specific mouse monoclonal antibody JF5 
(mJF5) [12]. The full-length humanised antibody was 
created using a human IgG1 framework and mJF5 
variable regions, by grafting the murine 
complementary determining regions (CDR) 
sequences onto human antibody donor sequences.  
Cell culture 
 All culture media was supplied by Invitrogen 
(UK) and supplemented with 8 mM L-glutamine 
(25030-024, Invitrogen) unless otherwise stated. CD 
DG44 medium (12610-010, Invitrogen) was 
supplemented with 1.8 % Pluronic F68 (24040-032, 
Invitrogen) prior to use. All cells were incubated at 37 
°C with 8 % CO2 in vented Erlenmeyer flasks (431143, 
431144, 431145, Corning, Netherlands), with shaking 
on a Labnet orbital 1000 shaking platform (ST2060, 
Appleton Woods Ltd., UK) rotating at 135 rpm unless 
otherwise stated. Cells were passaged by 
centrifugation at 300 g for 5 minutes and 
re-suspension in appropriate medium, and cell 
numbers and viabilities were determined using a 
hemocytometer and Trypan blue exclusion, 
respectively. 
Expression vectors 
 The gene coding for dihydrofolate reductase 
(DHFR) expression was cloned into the expression 
vector pVitro1-neo-mcs (Autogen-Bioclear UK Ltd., 
UK) following the internal ribosome entry sites (IRES) 
sequence, to generate pVitro DHFR3. DNA encoding 
the full-length 150 kDa antibody (hereafter referred to 
as Ab633) was cloned into the pVitro DHFR3 
mammalian expression vector. 
Transient transfection 
 Suspension adapted Chinese Hamster Ovary 
(CHO) K1 cells, were routinely cultivated at 2.0 - 3.0 x 
105 cells/ml at 150 rpm, in Pro CHO 4 serum free 
medium (BE12-029Q, Lonza, UK) plus 100 µM 
hypoxanthine/16 µM thymidine (H/T) (11607-030, 
Invitrogen). 1 x 108 cells were transfected with 1.25 
µg/ml of DNA (Ab633 pVitro DHFR3) in Pro CHO 5 
medium (BE12-766Q, Lonza) supplemented with 
H/T. Cultures were incubated for 11 days at 150 rpm. 
Medium scale transient transfection expression 
analysis was carried out to determine expression 
yields from CHO cells, with cell line Ab633-HC3-LC2 
taken forward for stable transfection. 
Stable transfection 
Linearisation of Ab633 pVitro DHFR3 vector 
 One hundred and fifty µg of Ab633-HC3-LC2 
pVitro DHFR3 was linearised in a restriction reaction 
consisting of 176 μl of endonuclease free water, 30 µl 
of NE buffer 2 (R0547S, New England Biolabs, UK), 3 
µl of 100X BSA (R0547S, New England Biolabs) and 5 
µl of Pac1 (R0547S, New England Biolabs). The digest 
was incubated at 37 °C overnight and then purified. 
Purification of Ab633 plasmid 
 Six hundred µl of cold ethanol was added to 300 
µl of linearisation mix and incubated on ice for 5 
minutes. Following centrifugation at 16,200 g at room 
temperature for 30 min the pellet was washed in 1 ml 
of 70 % ethanol and centrifuged for 10 min at 16,200 g. 
Following removal of the supernatant, the pellet was 
air dried for 30 minutes and 100 µl of endotoxin-free 
water was added to the pellet and dissolved overnight 
at 4 °C. One µl of the linearised plasmid was run on a 
1.5 % agarose gel and visualized on a Kodak gel 
imager. The DNA concentration was calculated using 
a spectrophotometer (SmartSpec reader, Bio-Rad, US). 
Transfection 
 Prior to transfection, cGMP CHO DG44 cells 
(A11000-01, Invitrogen) were routinely cultured in 
CD DG44 medium. Cells were diluted to a 
concentration of 3.0 x 105 cells/ml, incubated with 
shaking at 165 rpm, and passaged every 3-4 days. 
Twenty-four hours prior to transfection, DG44 cells 
were seeded, at a density of 7.0 x 105 cells/ml, into 80 
ml of CD DG44 medium and shaken at 165 rpm. On 
the day of transfection, 1.5 x 107 DG44 cells were 
seeded into 30 ml CD DG44 medium in a T175 flask 
(431080, Corning, US), and allowed to attach for 2 
hours in static culture. Fifteen µl of Freestyle Max 
transfection reagent (16447-100, Invitrogen) was 
added to 18 µg total of linearised Ab633 pVitro 
DHFR3 vector diluted in 600 µl OptiPRO serum free 
medium (12309-019, Invitrogen), and incubated for 10 
min at room temperature. The transfection mix was 
added drop wise to the T175 flask of cells and 
incubated, as a static culture, for 48 h. Following 
transfection, stably transfected cells were selected by 
culture in CD OptiCHO medium (12681029, 
Invitrogen) in T175 flasks, at a concentration of 1.0 x 
106 cells/ml. Cells were passaged until the viability 
was seen to begin to recover, and the culture was 
transferred to shaking cultures at 3.0 x 105 cells/ml 
and incubated for 3-4 days. Cells were then seeded in 
CD OptiCHO selection medium supplemented with 
500 µg/ml G418 sulfate (ant-gn-5, Autogen-Bioclear). 
Cells were routinely passaged by dilution in fresh 
selection medium at a density of 3.0 x 105 cells/ml 
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every 3-4 days until the viability was seen to increase 
to >90 % and a stable pool of cells was generated 
which expressed Ab633-HC3-LC2. Cell line T1 was 
selected for genomic amplification as it had the 
highest antibody production in picograms/cell/day 
(PCD) of 0.9. 
Genomic amplification and sub-cloning  
 A culture of Ab633-HC3-LC2-T1 with a viability 
of >90 % was subjected to a single round of 
amplification in amplification medium (CD OptiCHO 
medium supplemented with 500 µg/ml G418 and 500 
nM Methotrexate (A6770, Sigma, UK)). Cultures were 
seeded at 5.0 x 105 cells/ml and passaged every 4-5 
days in amplification medium until the culture was 
observed to recover viability to >90 %. Cells were then 
routinely passaged at 3.0 x 105 cells/ml with 
incubation for 3-4 days. Cells were subsequently 
sub-cloned by limiting dilution to ensure 
monoclonality. The cloning medium consisted of 60 % 
(v/v) conditioned medium (no L-glutamine), 35.5 % 
CD OptiCHO medium, 3 % 200 mM L glutamine, 1 % 
100X H/T, 0.3 % Phenol red (P0290, Sigma), and 500 
nM Methotrexate. The sub-clone Ab633-HC3-LC2-T1- 
1B3 with a PCD of 17.1 was selected and, after a 
second round of sub-cloning by limiting dilution, 
sub-clone 1G10 with a PCD of 33.5 was selected. 
Culture and preservation of 
Ab633-HC3-LC2-T1-1B3-1G10 cell line 
 Following adaptation to shaking culture, the cell 
line Ab633-HC3-LC2-T1-1B3-1G10 was routinely 
cultured in CD OptiCHO culture medium 
supplemented with 500 nM MTX and 1.0 % (v/v) 
dextran sulphate (D49110, Sigma) by seeding at 3.0 x 
105 cells/ml. Once cell viability had dropped to 
approximately 50 %, cultures were harvested. Cell 
cultures with viabilities >90 % were frozen at -80 °C in 
freezing medium (46.25 % conditioned medium, 46.25 
% fresh medium, 7.5 % sterile DMSO (D2650, Sigma)) 
prior to transfer to the vapour phase of liquid nitrogen 
for long-term storage. The cell line 
Ab633-HC3-LC2-T1-1B3-1G10 was deposited in the 
European Collection of Cell Cultures at Public Health 
England (Porton Down, UK; Patent Deposit Reference 
Number 15032401).  
Production and purification of antibodies 
For the production and purification of mJF5, the 
procedures described previously [8] were used. For 
purification of the humanised JF5 antibody (hereafter 
referred to as hJF5) from the cell line 
Ab633-HC3-LC2-T1-1B3-1G10, culture supernatants 
were harvested by centrifugation at 2147 g for 40 min 
at 4 °C, followed by filtration through a 0.8 μM 
cellulose acetate filter (10462240, GE Healthcare Life 
Sciences, UK). Culture supernatant was loaded onto a 
HiTrap Protein A column (17-0402-01, GE Healthcare 
Life Sciences) using a peristaltic pump P-1 
(18-1110-91, GE Healthcare Life Sciences) with a low 
pulsation flow of 1 ml/minute. Columns were 
equilibrated with 10 ml of phosphate-buffered saline 
(PBS), and column-bound antibody was eluted with 5 
ml of 0.1 M glycine-HCL buffer (pH 2.5) with a flow 
rate of 0.5 ml/min. The buffer of the purified antibody 
was exchanged to PBS using a disposable PD-10 
desalting column (17-0851-01, GE Healthcare Life 
Sciences). Following purification, the antibody was 
sterile filtered with a 0.24 µm syringe filter 
(85037-574-44, Sartorius UK, Ltd., UK) and stored at 4 
°C. Protein concentration was determined using a 
spectrophotometer (Nanodrop 1000, Thermo Fisher 
Scientific, USA), and purity was confirmed by 
sodium-dodecyl-sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and gel staining using 
Coomassie Brilliant Blue R-250 dye (Thermo Fisher 
Scientific). 
Mouse strains 
 Eight to 14-week-old female C57BL/6 OlaHsd 
mice were purchased from Envigo (Huntingdon, 
Cambridgeshire, UK). The animals were kept under 
standardized and sterile environmental conditions (20 
± 1 °C room temperature, 50 ± 10 % relative humidity, 
12 h light-dark cycle) and received food and water ad 
libitum. All experiments were performed according to 
the German Animal Protection Law with permission 
from the responsible local authorities (Tübingen, 
Magdeburg, Essen; Germany).  
Production of A. fumigatus inoculum  
 For intratracheal infection of animals, the 
wild-type Aspergillus fumigatus strain ATCC 46645 
was used. The fungus was grown on Aspergillus 
minimal medium (AMM) containing 56 mM 
D(+)glucose, 70 mM sodium nitrate, 7 mM potassium 
chloride, 11 mM potassium dihydrogen 
orthophosphate, 2 mM magnesium sulfate, 1x 
Hutner’s trace elements and 30 g agar per liter for 
spore production. Conidia were harvested after 3 
days of incubation at 37 °C by flushing with PBS and 
subsequent filtering through a cell strainer (40 μm 
pore size). 
Generation of A. fumigatus 
UDP-galactopyranose mutase-deficient 
mutants 
 Targeted replacement of the A. fumigatus 
UDP-galactopyranose mutase-encoding gene glfA, 
with the hygromycin B phosphotransferase-encoding 
gene (hph), was performed using the split marker 
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recombination method [18-20]. The glfA gene and 
flanking sequences were obtained from the Aspergillus 
Genome Database (AspGD, http://www.aspergillus
genome.org/) and used to design primers accordingly 
(Table S1). Primer pairs glf50.1F/glf50.1R and 
glf30.1F/glf30.1R were used to amplify the 5’ (LF, 
1.0-kb) and 3’ (RF, 1.0-kb) flanking regions of the glfA 
gene, respectively, from A. fumigatus Af293 genomic 
DNA. Simultaneously, split hph templates were 
amplified to create the 5’ amplicon (HY, 1.2-kb) using 
primers HY split/M13F, and 3’ amplicon (YG, 0.8-kb) 
using primers YG split/M13R. Fusion PCR resulted in 
two products, LFHY (2.1-kb) and RFYG (1.8-kb), 
using primer pairs glf50.4F/HY split and 
glf30.1R/nested YG split, respectively. The amplicons 
were gel-purified and transformed into protoplasts of 
Af293, replacing glfA with the assembled hph gene and 
conferring resistance to hygromycin B. Putative 
∆glfA::hph transformants were selected in the presence 
of hygromycin B (600µg/mL) and gene replacement 
was confirmed by Southern blot. The restriction 
enzyme Xba1 was used for digestion of genomic DNA 
prior to gel electrophoresis and blotting onto 
Hybond-NX membrane. The membrane was probed a 
1.0-kb fragment of the glfA ORF, amplified from A. 
fumigatus genomic DNA using the primer pair 
PROBEF/PROBER. The probe was predicted to 
hybridise to a 3.6-kb fragment present in Af293 that, if 
successfully deleted, would not be present in the 
mutant strains. Therefore, absence of the 3.6-kb band 
in Southern blots of digested genomic DNA would 
show successful deletion of the glfA gene.  
Phenotypic characterisation of mutants 
 For each strain, a 20 µl drop containing spores at 
a concentration of 103 spores/ml, was used to 
inoculate the centre of a malt extract agar (MEA) plate 
and then allowed to air dry. Plates were incubated at 
30 °C and 37 °C for 3 days, after which plates were 
scanned and the area of growth (mm2) was measured 
using Image J software (United States National 
Institutes of Health, Bethesda, Maryland, USA). This 
data was further analysed using SPSS to perform an 
ANOVA with post hoc Tukey-Kramer analysis. 
Ten-ml flasks of malt extract broth (MEB) were 
inoculated with spores to a final concentration of 104 
spores/ml and incubated at 30 °C and agitation at 60 
rpm. At 24 hour intervals, replicates of each strain 
were removed and culture fluids separated from 
mycelia by centrifugation at 4000 rpm for 10 min. 
Mycelial biomass was dried for 2 days at 80 °C, 
weighed, and culture filtrates assayed with mAbs 
mJF5 and hJF5 by using ELISA and western blotting.  
Immunoassays 
 Recognition of ∆glfA::hph mutant strains and 
wild-type strain Af293 by mAbs mJF5 and hJF5 was 
determined in ELISA, western blotting and 
immunofluorescence studies. For ELISA tests, 50 µl 
volumes of MEB culture fluids (or MEB only as a 
negative control), were used to coat wells of microtiter 
plates and incubated at 4 °C for 16 hours to allow 
antigen immobilisation. Wells were washed three 
times with PBST (PBS (0.8 % NaCl; 0.02 % KCl; 0.115 
% Na2HPO4; 0.02 % KH2PO4; pH 7.2) containing 0.05 
% (v/v) Tween-20), once with PBS and once with 
dH2O before being air-dried at 23 °C in a laminar flow 
hood. Wells were blocked for 15 min using 150 µl PBS 
containing 1 % (w/v) bovine serum albumin (BSA) 
and rinsed with PBS prior to adding PBST containing 
4 µg/ml of Protein A-purified mJF5 or hJF5 antibody 
to each well. The plates were incubated for 1 hour and 
then washed 3 times with PBST (5 min each) before 
secondary antibody was added for 1 hour. For hJF5, 
goat anti-human polyvalent immunoglobulins (G, A, 
M) peroxidase conjugate (A8400, Sigma) was used at a 
concentration of 1:1000 in PBST, while a 1:1000 PBST 
dilution of goat anti-mouse polyvalent 
immunoglobulins (G, A, M) peroxidase conjugate 
(A0412, Sigma) was used for mJF5. After washing 
wells 3 times with PBST and once with PBS, 
tetramethyl benzidine substrate solution [21] was 
added to the wells and incubated for 30 min. 
Reactions were stopped with 3 M H2SO4 and 
absorbance measured at 450 nm using a microplate 
reader (Tecan GENios, Tecan Austria GmbH). 
Working volumes were 50 µl and all incubation steps 
were performed at 23 °C in sealed plastic bags.  
 Having shown in ELISA tests that strongest 
recognition of the mannoprotein antigen by mAbs 
mJF5 and hJF5 was achieved with day 3 culture fluids 
of Af293, 3-day-old culture fluids from the wild-type 
and mutant strains were subjected to 
sodium-dodecyl-sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blotting. For 
SDS-PAGE, culture filtrates were mixed 1:1 (v/v) with 
Laemmli buffer [22] and were denatured by heating at 
95 oC for 10 min. Antigens were separated in 4-20 % 
(w/v) polyacrylamide gradient gels (161-1159, 
Bio-Rad) for 1.5 hours at 23 oC (165V) under 
denaturing conditions, and pre-stained broad range 
markers (161-0318, Bio-Rad) were used for molecular 
weight determinations. For westerns, separated 
antigens were transferred electrophoretically to a 
PVDF membrane (162-0175, Bio-Rad). The 
membranes were blocked for 16 hours at 4 oC with 
PBS containing 1 % (w/v) BSA and incubated with 
Protein A-purified mJF5 or hJF5 (both at 2 µg 
protein/ml) in PBS containing 0.5 % (w/v) BSA 
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(PBSA) for 2 h at 23 oC. After washing three times 
with PBS, membranes were incubated for 1 h with 
goat anti-mouse polyvalent immunoglobulins (G, A, 
M) peroxidase conjugate (A0412, Sigma) or goat 
anti-human polyvalent immunoglobulins (G, A, M) 
peroxidase conjugate (A8400, Sigma), both diluted 
1:1000 in PBSA. After washing twice with PBS and 
once with PBST, the membranes were incubated for 5 
min in Amersham ECL western blotting detection 
reagent (RPN2106, GE Healthcare Lifesciences) and 
chemiluminescence was measured at 428 nm using a 
gel doc system (Syngene G, Box, Syngene UK). 
 For immunofluorescence (IF), sterilised glass 
slides were coated with washed spore suspensions 
containing 1 % (w/v) glucose solution and incubated 
at 30 °C for 16 hours to allow spore germination and 
formation of germ tubes. After air-drying, the cells 
were fixed to the slides [21] and incubated with 
Protein A-purified mJF5 or hJF5 diluted to 2 µg 
protein/ml in PBS for 1 h, followed by three 5 min 
PBS washes. Slides were then incubated with goat 
anti-mouse polyvalent fluorescein isothiocyanate 
(FITC) conjugate (F1010, Sigma) or goat anti-human 
IgG (Fc specific) FITC conjugate (F9512, Sigma), each 
diluted 1 in 40 in PBS, for 30 min. Slides were given 
three 5 min washes with PBS and mounted in 
PBS-glycerol mounting medium (F4680, Sigma) before 
overlaying with coverslips. All incubation steps were 
performed at 23 °C in a humid environment to 
prevent evaporation and slides were stored in the 
dark, at 4 °C, prior to examination using an 
epifluorescence microscope (Olympus IX81) fitted 
with 495 nm (excitation) and 518 nm (emission) filters 
for FITC. 
A. fumigatus infection procedure 
 To induce neutropenia, mice received an 
intraperitoneal (i.p.) injection of 100 µg of a 1 mg/ml 
solution of anti-Ly-6G/anti-Ly6C antibody (clone 
RB6-8C5, BioXCell, West Lebanon, NH, USA) 24 
hours prior to the infection procedure. For pulmonary 
infection, animals were anesthetized with an i.p. 
injection of 100 µl Ketamin/Rompun solution 
(Ketamin: [80 mg/kg], Ratiopharm GmbH, Ulm, 
Germany; Rompun: [15 mg/kg], Bayer HealthCare, 
Leverkusen, Germany). After reaching deep narcosis, 
mice were intubated using a 22-gauge indwelling 
venous catheter (Vasofix Braunüle, B. Braun AG, 
Melsungen, Germany) and 100 μl of the freshly 
prepared A. fumigatus spore suspension (4 x 106/ml) 
was applied. Animals were ventilated for 1 min with a 
small animal respirator (MiniVent, Hugo Sachs, 
March-Hugstetten, Germany) at a rate of 250 breaths 
per minute and an inhalation volume of 300 μl per 
breath to achieve a better distribution of the spores. 
Control animals received an equivalent volume of 
phosphate-buffered saline only (DPBS, Life 
Technologies, Carlsbad, CA, USA). 
Fluorescence microscopy of infected lungs 
 For fluorescence microscopy, purified hJF5 IgG1 
antibody or human IgG1 isotype control antibody 
(clone ET901, Biolegend, USA) were coupled to 
DyLight650 (Thermo Fisher Scientific) and were used 
in in situ and in vivo studies of A. fumigatus lung 
infections as described previously [8]. 
Chelator conjugation of antibodies 
hJF5 antibody and human IgG1 isotype control 
antibody 
 For conjugation to chelators, purified mAb hJF5 
was first incubated with EDTA (0.5 mM) for 45 min at 
room temperature with gentle shaking to remove 
metal contamination. Trace-metal basis 0.1M boric 
acid (Sigma-Aldrich, Switzerland), pH 9.1, 
equilibrated with PD-10 (GE Healthcare, 
Switzerland), was used for buffer exchange and to 
remove excess EDTA from the hJF5 antibody. Eluted 
antibody was collected in Amicon Ultra-15 centrifugal 
filter units with a molecular weight cut off of 10 kDa 
(Merck Millipore, Switzerland). Chelators 
p-NCS-Bz-DOTAGA or p-NCS-Bz-NODAGA 
(Chematech, France) were dissolved in DMSO at 33.3 
mM and were applied at a 20-fold molar excess versus 
the antibody (33.3 µM). The conjugation reaction was 
carried out at 4 °C for 16 hours and, after purification 
with a PD-10 column, the antibody was equilibrated 
in Chelex-treated PBS, pH 7.4 (Bio-Rad, Switzerland). 
The eluted conjugate was collected in an Amicon 
Ultra-15 centrifugal filter unit (10 kDa molecular 
weight cut off) and was purified two more times with 
Chelex-treated PBS (pH 7.4). NODAGA-NCS 
conjugation of the isotype IgG1 control antibody 
ET901 was performed in the same manner as above, 
but with a 25 molar excess compared to the antibody 
(33.3 µM). 
mJF5 
 Protein A-purified mAb mJF5 (IgG3) was buffer 
exchanged using PBS (pH 7.4, Chelex-treated) 
equilibrated PD-10. Eluted antibody was collected in 
Amicon Ultra-15 centrifugal filter units (10 kDa 
molecular weight cut-off). p-NCS-Bz-DOTA-GA or 
p-NCS-Bz-NODA-GA chelators were dissolved in 
DMSO at 33.33 mM and were applied at a 13-fold 
molar excess versus the antibody (13.33 µM). The 
conjugation reaction was carried out for 16 hours at 37 
°C, with subsequent antibody purification via a PD-10 
column. The antibody was equilibrated in 
Chelex-treated PBS (pH 7.4). The eluted conjugate 
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was collected in an Amicon Ultra-15 centrifugal filter 
unit (molecular weight cut off: 10 kDa) and was 
purified two more times with Chelex-treated PBS (pH 
7.4). 
Determination of antibody-to-chelator ratio 
 Antibody-to-chelator ratios were determined 
with a LC-MS-ESI (Waters LCT Premier mass 
spectrometer). Antibody samples were 
de-glycosylated overnight using PNGase F (Roche, 
Switzerland), and reduced with 50 mM DTT 
containing 0.5 mM EDTA for 30 min at 37 °C. The 
samples were chromatographed on an Aeris 
WIDEPORE XB-C18 column (3.6 μm, 100 mm x 2.1 
mm; Phenomenex, USA) at 80 °C. The following 
gradient was applied: 0-3min with 20 % A, 75 % B, 
and 5 % C; 3-18 min with 22 % A, 73 % B, and 5 % C; 
18-20 min with 85 % A, 10 % B, and 5 % C (where A = 
acetonitrile containing 0.1% formic acid, B = water 
containing 0.1 % formic acid, and C = isopropanol) 
using a constant flow of 0.5 mL/min. MassLynxV4.1 
was applied for data collection, and MaxEnt1 for data 
deconvolution.  
Immuno-reactivities and serum stabilities of 
the mJF5 and hJF5 antibodies and their 
DOTAGA and NODAGA chelator derivatives 
 Immuno-reactivities of the antibodies and their 
chelator derivatives were determined in ELISA, 
western blotting and IF studies as described, with 
modifications. For ELISA and western blotting 
studies, purified Aspergillus mannoprotein antigen [8] 
was used in place of Aspergillus culture filtrates, with 
microtiter plates coated with saturating 
concentrations of antigen (1 mg antigen/mL PBS). For 
western blotting studies, purified antigen was 
denatured in Laemmli buffer at 0.5 mg/mL buffer, 
and 40 µL volumes subjected to SDS-PAGE, 
electrophoretic transfer to PVDF and processing with 
antibodies as described.  
For serum stability tests, one volume of the 
respective chelator-conjugated (DOTAGA, 
NODAGA), 64Cu-labeled JF5 antibodies (mJF5, hJF5) 
in their final formulations were cleaned with a 
Bio-Spin 6 column and each was incubated with three 
volumes of C57BL/6 serum at 37 °C. The samples 
were removed after 1h, 24h, and 48 h and 
immediately analyzed by radio high-performance size 
exclusion chromatography (HPSEC; Phenomenex 
Biosep SEC-s3000, 1.5 mL/min saline sodium citrate). 
In addition, the samples were run on iTLC-SG paper 
with 0.1 M sodium citrate (pH 5.0) and analyzed using 
autoradiography.  
PET tracer production and radiolabeling of 
antibodies 
 64Cu was produced at the in-house 
radiopharmacy of the Department of Preclinical 
Imaging and Radiopharmacy in Tübingen, using a 
PETtrace cyclotron (General Electric Medical Systems 
(GEMS). 64Cu was generated by 12.5 MeV proton 
irradiation of enriched 64Ni metal (35-75 mg; Isoflex, 
>98 % enrichment) electroplated on a 
platinum/iridium disc via the 64Ni(p,n)64Cu nuclear 
reaction as described previously [8]. In brief, 64Cu was 
separated from the bulk nickel target and other 
metallic impurities by acid dissolution followed by 
anion exchange chromatography (AG1 × 8, Biorad) in 
aqueous hydrochloric acid media (Trace Select, Sigma 
Aldrich). The fractions containing the 64Cu product 
were dried under argon at 120 °C.  
 For antibody radiolabeling, the dry 64CuCl2 was 
re-dissolved in 0.1 M HCl and the pH was adjusted to 
6–7 using 0.5 M ammonium acetate. Two µg of 
p-NCS-Bz-DOTAGA or p-NCS-benzyl-NODAGA 
conjugated antibodies (NODAGA-mJF5, 
DOTAGA-mJF5, NODAGA-hJF5, NODAGA-isotype 
IgG1 control ET901) was added per MBq of 64Cu and 
incubated at 42 °C for 60 min. Thin layer 
chromatography (Polygram SIL G/UV254, 
Macherey-Nagel; mobile phase: 0.1 M sodium citrate, 
pH 5.0) and HPSEC (Phenomenex BioSep SEC-s3000 
300 x 4.6 mm, 1.5 ml/min saline sodium citrate) were 
conducted for quality control of the radiolabeled 
antibodies. 
PET/MR imaging, ex vivo biodistribution and 
autoradiography 
 The animal infection and imaging protocol (Fig. 
S2) included simultaneous PET/MR imaging of A. 
fumigatus-infected and non-infected control mice at 
three consecutive time points (3 h, 24 h, and 48 h 
post-infection (p.i.)) in groups of n=4-5. In vivo 
biodistributions of the respective antibody-based PET 
tracers were assessed using a small animal PET insert 
(Bruker Biospin GmbH, Ettlingen, Germany) yielding 
a spatial resolution of approximately 1.3 mm in the 
reconstructed images [23]. For administration of 
tracers, animals were anaesthetised briefly with 1.5 % 
isoflurane and 0.8 L/min 100 % oxygen, and injected 
intravenously (i.v.) with 20 µg of 
[64Cu]DOTAGA-labeled or [64Cu]NODAGA-labeled 
mJF5 antibody, [64Cu]NODAGA-labeled hJF5 
antibody, or [64Cu]NODAGA-labeled isotype control 
antibody ET901, corresponding to 12-14 MBq for 
immunoPET imaging. Static PET scans (10 min) were 
acquired 3 h, 24 h and 48 h after the injection of the 
respective tracer. During PET and MR imaging, the 
animals were anesthetized with 1.5 % isoflurane 
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mixed with 100 % oxygen. PET data were acquired in 
list-mode, histogrammed in one 10 min time frame 
and reconstructed using a 2D iterative ordered subset 
expectation maximization (OSEM2D) algorithm. MR 
imaging was performed on a 7 T, 300 MHz small 
animal MR tomograph (Bruker Biospin GmbH) for 
the acquisition of anatomical information. The images 
were acquired using a T2 fat saturated 3D sequence 
with a TE/TR of 90.51/1800.000 ms. Additionally, a 
T1 3D fast low angle shot (FLASH) sequence with a 
TE/TR of 6.000/30.000 ms was performed. PET 
images were normalized to each other, subsequently 
fused to the respective MR images and analyzed 
using Inveon Research Workplace software (Siemens 
Preclinical Solutions, Knoxville, TN, USA). Regions of 
interest (ROIs) were drawn around the respective 
tissues based on the anatomical information from the 
MR images. Absolute quantification of the PET data is 
expressed as percentage of the injected dose per cubic 
centimeter (%ID/cc). After the final PET scan, all 
animals were sacrificed by cervical dislocation under 
deep anesthesia and dissected. Organs were removed 
and radioactivity was quantified with an aliquot of 
the injected radiotracer in a γ-counter (Wallac 2480 
WIZARD 3”, Perkin-Elmer, Waltham, MA, USA) 
using an energy window between 350 and 650 keV. 
The results are expressed as % injected dose per g 
(%ID/g) of tissue. Autoradiography was also 
performed after the last PET scan. Animals were 
sacrificed, the lungs were carefully dissected, 
embedded in optimal cutting temperature compound 
(TissueTek, Sakura, Zoeterwonde, The Netherlands) 
and snap frozen. Twenty µm cryosections of tissue 
were exposed for 24 h to phosphor screens and 
autoradiograms were acquired with a storage 
phosphor imager (445SI, Molecular Dynamics, 
Sunnyvale, CA, USA). The spatial resolution of the 
phosphor imager was set to 50 µm. The 
autoradiography data were analyzed using ImageJ 
software and normalized to the injected dose. The 
same tissue slices used for the autoradiography were 
stained with hematoxylin and eosin (H&E) following 
standard procedures. Subsequently, the slides were 
scanned using the digital slide scanner NanoZoomer 
2.0-HT (Hamamatsu Photonics K.K., Hamamatsu, 
Japan). 
Statistical analysis 
 For experiments with more than two 
investigated groups, p-values were calculated using 
one-way analysis of variance (ANOVA) followed by 
Tukey’s multiple comparison test conducted with 
Origin 8 software (OriginLab Corporation, 
Northampton, MA, USA). Means were considered 
statistically significant at *P < 0.05. Unless otherwise 
stated, all quantitative data are shown as the mean ± 1 
standard deviation (SD). 
Results 
Characterisation of the hJF5 antibody  
 The amino acid sequences of the heavy and light 
chains of the humanised antibody 
Ab633-HC3-LC2-T1-1B3-1G10 (hJF5) are shown in 
Fig. 1A. The full length humanized antibody hJF5 
comprising heavy and light chains (Fig. 1B) showed 
characteristic binding in western blots to purified 
Aspergillus mannoprotein, with molecular weights of 
~36 kDa to >210 kDa (Fig. 1C). The pattern of staining 
was consistent with that of the mouse antibody mJF5 
(Fig. 1C). To further test the immuno-reactivities of 
the unlabeled and chelator-labeled antibodies after 
modification, additional in vitro tests were performed. 
Immunoreactivity of the mJF5 antibody following 
labeling with the chelators DOTAGA and NODAGA 
was investigated in ELISA tests. There was no 
significant loss in mJF5 immunoreactivity in ELISA, 
using a saturating concentration of purified 
mannoprotein antigen, as a consequence of labeling 
with the two chelators (Fig. 1D). Similarly, there was 
no notable loss in hJF5 immunoreactivity following 
labeling with NODAGA. Indeed, both the unlabeled 
and NODAGA-labeled hJF5 antibodies showed 
increased binding to the mannoprotein target, 
compared to mJF5 and its chelator derivatives, at 
equivalent antibody protein concentrations. The 
human IgG1 isotype control antibody ET901 
conjugated to NODAGA showed no binding to the 
target antigen in ELISA tests (Fig. 1D). Labeling of the 
hJF5 antibody with NODAGA did not alter the 
hyphal-specific nature of the antibody to its target 
mannoprotein antigen (Fig. 1E). Intense 
immunofluorescence of hyphae, but lack of staining of 
un-germinated spores of the fungus (marked by 
asterisks), was observed with unconjugated mJF5, 
unconjugated hJF5, and NODAGA-labeled hJF5. No 
fluorescence was found using the IgG1 isotype control 
antibody ET901 conjugated to NODAGA, further 
demonstrating the specificities of the mJF5 and hJF5 
antibodies. 
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Figure 1. Immuno-reactivities of the mJF5 and hJF5 antibodies and their DOTAGA and NODAGA chelator-labeled derivatives. A. Amino acid sequences of the 
heavy and light chains of the humanised antibody Ab633-HC3-LC2-T1-1B3-1G10 (hJF5); the signal peptides (cleaved off in the mature antibody) are highlighted in 
green, the variable domains are highlighted in blue, and the constant domains are highlighted in orange. B. Purity of the Protein A-purified antibody hJF5, with heavy 
and light chains of ~50kDa and ~31kDa respectively, determined by using SDS-PAGE under denaturing conditions followed by Coomassie staining. C. Western 
immunoblots using the purified hJF5 antibody (left) and mJF5 antibody (right) tested against purified Aspergillus mannoprotein antigen. Wells were loaded with 40 µl 
of a 0.5 mg/mL solution of antigen denatured in Laemmli buffer. Both antibodies show a characteristic smearing pattern, binding to glycoprotein antigen with 
molecular weights of between ~36 kDa and >210 kDa. D. ELISA of mJF5, hJF5, human IgG1 isotype control antibody ET901, and non-radiolabeled DOTAGA- or 
NODAGA-conjugated antibody derivatives, using microtiter plates coated with 1 mg/mL of purified Aspergillus mannoprotein antigen. No notable reductions in 
binding of the mJF5 and hJF5 antibodies are apparent as a result of conjugation to the chelators DOTAGA or NODAGA. Note, however, the increase in binding of 
the hJF5 and NODAGA-hJF5 antibodies compared to the mJF5 and NODAGA-mJF5 counterparts at equivalent antibody protein concentrations. The lack of binding 
of the NODAGA-conjugated human IgG1 isotype control ET901, demonstrates the specific binding of the mJF5 and hJF5 antibodies to the target antigen, and is 
confirmed by the molecular imaging studies in vivo. E. Immunofluorescence of germinating spores of Af293 using mJF5, hJF5, NODAGA-hJF5, and NODAGA-ET901. 
Brightfield images of cells are shown alongside their corresponding epifluorescence images following staining of the cells with the antibodies and FITC conjugates. 
Under epifluorescence, mJF5, hJF5 and NODAGA-hJF5 can be seen to bind to extracellular cell-wall bound antigen displayed on the surface of Af293 germ tubes, 
while the NODAGA conjugated human IgG1 isotype control antibody shows no fluorescence, consistent with hyphal-specific binding of the mJF5 and hJF5 antibodies. 
The scale bar that applies to all of the images = 6 µm. 
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Figure 2. Characterisation of the epitopes bound by mAbs mJF5 and hJF5. A. Genomic DNA of the Aspergillus fumigatus wild-type strain Af293 and the putative 
UDP-galactopyranose mutase-deficient mutants ∆glfA::hph4.4 and ∆glfA::hph7.4 (left panel), was digested with the restriction enzymes Xba1, fractionated by gel 
electrophoresis and blotted onto Hybond-NX membrane; the Southern blot (right panel) was probed with a 1.0-kb fragment of the glfA ORF. Note the presence of 
the predicted 3.6-kb band in the wild type strain, but absence in ∆glfA::hph4.4 and ∆glfA::hph7.4, showing successful deletion of the glfA gene in the mutant strains. B. 
ELISA of extracellular antigens in fluids from shake cultures of Af293 and mutants ∆glfA::hph4.4 and ∆glfA::hph7.4. While mAbs mJF5 and hJF5 showed strong 
recognition of secreted antigens in Af293 culture fluids, there was no recognition of antigens in the culture fluids of the mutant strains over the 4-day sampling period. 
C. Immunofluorescence of germinating spores of Af293 and the two mutant strains using mAbs mJF5 and hJF5. Brightfield images of cells are shown alongside their 
corresponding epifluorescence images following staining of the cells with the two antibodies and FITC conjugates. Under epifluorescence, both antibodies can be seen 
to bind to extracellular cell-wall bound antigen displayed on the surface of Af293 germ tubes, but there is no recognition of germinated spores of the wild-type strain, 
consistent with the hyphal-specific binding characteristics of the two antibodies. In contrast, neither antibody binds to the germ tubes of the two mutant strains. The 
scale bar that applies to all of the images = 4 µm. D. Western immunoblots using fluids from 3-day-old shake cultures of Af293 and the two mutant strains, shown in 
ELISA to contain greatest amounts antibody-reactive extracellular antigen from Af293 (Fig. 1B). Both mJF5 and hJF5 show a characteristic smearing pattern, binding 
to glycoproteins with molecular weights of between ~36 kDa and >210 kDa. In contrast, there is complete loss of antibody binding to extracellular antigens from 
corresponding 3-day-old shake culture fluids of ∆glfA::hph4.4 and ∆glfA::hph7.4.  
 
mJF5 and hJF5 bind to the epitope 
β1,5-galactofuranose (Galf) 
 Aspergillus fumigatus mutants deficient in the 
epitope β1,5-galactofuranose (Galf) were successfully 
generated by targeted deletion of the 
UDP-galactopyranose mutase-encoding gene glfA 
(Fig. 2A). Two independent mutant strains 
(∆glfA::hph4.4 and ∆glfA::hph7.4) showed characteristic 
reductions in growth at 30 °C and 37 °C compared to 
the wild-type strain Af293 (Fig. S1A), which is 
consistent with growth defects of A. fumigatus 
Galf-deficient mutants across a range of temperatures 
[16]. The mutants and Af293 were grown for 4 days in 
liquid shake cultures (Fig. S1B), and the 
corresponding fluids tested by ELISA using mAbs 
mJF5 and hJF5 (Fig. 2B). While the mAbs reacted 
strongly with extracellular antigen produced by 
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Af293, there was complete loss of binding to antigen 
produced by the mutants over the 4-day sampling 
period (Fig. 2B). The mutants were also shown to be 
deficient in the Galf epitope in IF and western blotting 
studies, with complete lack of binding of the 
antibodies to cell-wall bound and secreted antigens 
(Figs. 2C and 2D, respectively). Taken together, these 
results indicate that the mAbs bind to the epitope Galf 
present in secreted and cell wall bound 
(galacto)mannoproteins of A. fumigatus. 
hJF5 binds to A. fumigatus in vivo  
 The suitability of mJF5 as an intravital 
whole-body diagnostic antibody, when equipped 
with a suitable label, was demonstrated previously 
[8]. To determine the diagnostic accuracy of the newly 
developed hJF5 antibody, we first investigated 
whether fluorochrome-labeled hJF5 was able to detect 
A. fumigatus in infected lungs of experimental 
animals. Neutrophil-depleted mice were 
intra-tracheally (i.t.) infected with conidia of a 
genetically-modified strain of the fungus expressing 
the fluorescent protein tdTomato (A. fumigatustdTomato) 
and, 48 h later, the lungs were excised and tissue 
sections were probed with hJF5 or the IgG1 isotype 
control antibody ET901 both labeled with the 
fluorochrome DyLight650 (Fig. 3A). Large fluorescent 
(false colour green) masses of A. fumigatustdTomato 
mycelium were detected in both cases (Fig. 3B). 
However, while hJF5 gave an intense red fluorescence 
of fungal elements, the isotype control was negative 
(Fig. 3B). In a second set of experiments, the labeled 
hJF5 or control antibodies were injected 24 h after 
infection into the circulation of mice (Fig. 3C). After an 
additional 24 h, lung lobes were dissected and were 
examined under confocal microscopy (Fig. 3D). This 
also showed red fluorescence of the hJF5-DyLight650 
tracer which co-localised with green fluorescing 
fungal elements, with no fluorescence exhibited by 
the control. Individual hyphae showed green 
fluorescence of the A. fumigatustdTomato cytoplasm and 
specific binding of hJF5-DyLight650 (red) to the 
hyphal cell wall (Fig. 3E). The isotype controls were 
negative and showed green fluorescence of the hyphal 
cytoplasm only (Fig. 3E). 
PET/MR imaging of invasive pulmonary 
aspergillosis using [64Cu]DOTAGA-mJF5, 
[64Cu]NODAGA-mJF5 and 
[64Cu]NODAGA-hJF5 
For immunoPET imaging, mJF5 was conjugated 
with the chelators DOTAGA and NODAGA, and hJF5 
with the chelator NODAGA. The chelated antibodies 
were then labeled with the radionuclide 64Cu, which 
allows consecutive imaging for up to 3 d. The specific 
activities of the tracers used in the in vivo 
biodistribution studies was determined to be in the 
region of 500–625 MBq/mg. Radiolabeling efficiencies 
were determined by TLC with the 64Cu-labeled, 
chelator-conjugated antibodies [64Cu]DOTAGA-mJF5, 
[64Cu]NODAGA-mJF5 and [64Cu]NODAGA-hJF5 
having labeling efficiencies of 92%, 98% and 97%, 
respectively. The serum stabilities of the 
chelator-conjugated antibodies were determined by 
radio-HPSEC, with the analysis showing no signs of 
proteolytic degradation, protein aggregation or 
copper transchelation to serum proteins over a 48 h 
time period (Fig. S3). 
Neutropenic mice infected with A. fumigatus 
were injected with [64Cu]Cl2 only, [64Cu]NODAGA- 
isotype control antibody ET901, 
[64Cu]DOTAGA-mJF5, [64Cu]NODAGA-mJF5 or 
[64Cu]NODAGA-hJF5 and their biodistributions 
evaluated by PET/MRI at 3h (Fig. S4), 24 h (Fig. S5), 
and 48 h post infection (Fig. 4). Control mice were i.t. 
treated with PBS inducing sterile inflammation in the 
lung, but were otherwise treated the same.  
[64Cu]NODAGA-hJF5 improves the in vivo 
detection of A. fumigatus lung infections 
compared to [64Cu]DOTAGA-mJF5 and 
[64Cu]NODAGA-mJF5 
 PET images showed increased uptake of the 
antibody-based PET tracers [64Cu]DOTAGA-mJF5, 
[64Cu]NODAGA-mJF5 and [64Cu]NODAGA-hJF5 in 
the lungs of A. fumigatus-infected animals 48 h p.i., 
compared to the lungs of PBS-treated control mice or 
lungs of PBS control and A. fumigatus-infected mice 
injected with [64Cu]Cl2 only (Fig. 4A and 4C). In vivo 
quantification (Fig. 4E) showed higher uptake of the 
antibody-based tracers in the lungs of infected 
animals compared to the PBS-treated controls or 
infected and control animals injected with [64Cu]Cl2 
only. Results from in vivo PET imaging were 
confirmed by the ex vivo biodistribution data at 48 h 
p.i. (Table 1). The in vivo uptake of 
[64Cu]NODAGA-hJF5 48 h p.i. in the lungs of infected 
animals (17.1 ± 2.5 %ID/cc) was higher than in the 
lungs of the corresponding PBS-treated control 
animals (9.4 ± 1.1 %ID/cc; Fig. 4E). The ex vivo 
biodistribution results similarly showed higher 
uptake of [64Cu]NODAGA-hJF5 (33.8 ± 4.0 %ID/g) in 
the lungs of infected animals compared to the 
corresponding PBS-treated control animals (10.9 ± 
1.8%ID/g). A similar trend in in vivo lung uptake in 
infected animals was found with 
[64Cu]NODAGA-mJF5 (11.5 ± 2.8 %ID/cc) compared 
to the corresponding PBS-treated control animals (5.5 
± 0.6 %ID/cc), with ex vivo biodistribution values of 
31.6 ± 5.1 %ID/g and 7.7 ± 1.2 %ID/g, respectively. 
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While ex vivo biodistribution results (Table 1) revealed 
a higher uptake of [64Cu]DOTAGA-mJF5 in the lungs 
of infected animals (26.0 ± 5.4 %ID/g) compared to 
the corresponding PBS-treated controls (10.1 ± 1.9 
%ID/g), uptake of this tracer in the A. 
fumigatus-infected lung was less compared to the 
tracer [64Cu]NODAGA-mJF5. Taken together, the 
results show that the strength of uptake of the tracers 
in the A. fumigatus-infected lung followed the 
sequence [64Cu]NODAGA-hJF5 > 
[64Cu]NODAGA-mJF5 > [64Cu]DOTAGA-mJF5 > 
[64Cu]NODAGA-ET901 > [64Cu]Cl2 only, thereby 
showing that the uptake of [64Cu]NODAGA-hJF5 in 
the lungs of A. fumigatus infected mice was 
significantly higher compared to all other tested 
tracers 48 h p.i. Also the uptake of 
[64Cu]NODAGA-mJF5 in the lungs of A. fumigatus 
infected mice was significantly higher compared to 
[64Cu]Cl2 (Fig. 4E). This trend in uptake was further 
evidenced by ex vivo autoradiography of the lungs of 
infected and control animals (Fig. 4B and 4D).  
 
 
Figure 3. Binding specificity of hJF5 to A. fumigatus in infected mouse lungs. A. Experimental workflow for the in situ binding of mAb hJF5: (1) Neutrophil depletion by i.p. injection 
of 100 µg of the anti-Gr-1 antibody 17 h before injection with the pathogen; (2) Intra-tracheal infection with A. fumigatustdTomato; (3) After 48 h, the lungs were explanted, fixed, 
and fungal biomass stained in situ with DyLight650 conjugates of hJF5 or the human IgG1 isotype control antibody ET901. B. Micrographs of infected lungs showing cytoplasmic 
fluorescence (false colour green) of the genetically modified strain of the pathogen A. fumigatustdTomato, and co-localisation of cell-wall-bound mannoprotein antigen with the 
probes hJF5-DyLight650 (red fluorescence) or ET901-DyLight650 control (red fluorescence). Note red fluorescence of tissue probed with hJF5-DyLight650, but lack of 
fluorescence with the control antibody. Scale bar = 50 µm. C. Experimental workflow for hJF5 binding in vivo: (1) Neutrophil depletion by i.p. injection of 100 µg anti-Gr-1 
antibody (clone RB6-8C5) 17 h before injection with the pathogen; (2) Intra-tracheal infection with A. fumigatustdTomato; (3) i.v. injection of hJF5-DyLight650 or ET901-DyLight650 
antibodies 24 h after fungal infection; (4) Another 24 h later, the lungs were explanted and (5) longitudinal sections of explanted lung tissues were examined under confocal 
microscopy. D. Micrographs of A. fumigatustdTomato infected lungs (shown in false colour green) following i.v. injection with hJF5-DyLight650 (red) or ET901-DyLight650 (red). 
Note red fluorescence of lungs with hJF5-DyLight650, but lack of fluorescence with the control. Scale bar = 50 µm. E. An individual hypha is shown at higher magnification, with 
green fluorescence of A. fumigatustdTomato cytoplasm (white arrow) and binding of hJF5-DyLight650 (red) to the target mannoprotein antigen in the hyphal cell wall (white 
arrowhead). Note the lack of red fluorescence of the outer cell wall with the isotype control, further demonstrating the specificity of the hJF5 antibody. Scale bar = 2 µm.  
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Figure 4. In vivo biodistribution of [64Cu]Cl2, [64Cu]NODAGA-isotype control antibody ET901, [64Cu]DOTAGA-mJF5, [64Cu]NODAGA-mJF5 and 
[64Cu]NODAGA-hJF5 in PET/MR imaging at 48 h p.i. A and C. Coronal MIP, MR and fused PET/MR images of PBS treated mice and A. fumigatus infected mice injected 
with the respective tracers. The MR images of infected animals clearly reveal pulmonary infection and hyphal growth of A. fumigatus (hyperintense regions). The PET 
insert images of infected mice display specific lung uptake of the radiolabeled JF5 antibody-tracers compared to infected animals receiving [64Cu]Cl2 only or the 
64Cu-labeled isotype control antibody ET901. Additionally, the high liver uptake of [64Cu]Cl2 and [64Cu]DOTAGA-mJF5 in infected animals can be observed. B and 
D. Representative autoradiographic images with subsequent H&E staining of the lung tissue 48 h p.i. Autoradiographs of lung sections (right) with the corresponding 
H&E staining (left). Ex vivo autoradiography shows higher tracer accumulation in the lungs of infected animals receiving the JF5 antibody tracers compared to the 
respective PBS controls. Infected animals receiving the JF5 antibody tracers show higher signal intensities in the lung compared to the A. fumigatus infected mice 
receiving [64Cu]Cl2 or the control tracer [64Cu]NODAGA-isotype. Furthermore, higher uptake of [64Cu]NODAGA-hJF5 in the lungs of infected animals compared 
to the other infected groups can be observed. (E) Quantification of the PET images 48 h p.i. for lung tissues. Uptake of the various tracers in the lungs of infected 
animals compared to PBS controls at 48 h p.i. is shown in groups of n=4-5 mice. Significantly higher uptake of [64Cu]NODAGA-hJF5 in the lungs of A. fumigatus infected 
animals was obtained compared to all other tracers. Significantly higher lung uptake was also observed in infected animals injected with the tracer 
[64Cu]NODAGA-mJF5 compared to [64Cu]Cl2 . Data are expressed as the mean ± SD %ID/cc. Group differences were examined using one-way ANOVA, followed 
by post hoc Tukey–Kramer, *P < 0.05. 
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Table 1. Ex vivo biodistribution at 48 h p.i. The data confirm the results of the in vivo biodistribution obtained 48 h p.i. Significantly higher 
uptake of the [64Cu]DOTAGA-mJF5, [64Cu]NODAGA-mJF5 and [64Cu]NODAGA-hJF5 tracers in the lungs of infected animals compared 
to the corresponding PBS control animals confirm the specificities of the radiolabeled JF5 antibody tracers for the detection of IPA in vivo.  
 
Data are results of n=4-5 animals per group and expressed as the mean ± SD %ID/g. 
 
Conjugation of mJF5 and hJF5 antibodies to 
[64Cu]NODAGA gives non-specific liver 
enrichment similar to [64Cu]DOTAGA 
 In a previous study [8], we showed that while 
[64Cu]DOTA-mJF5 allowed specific detection of A. 
fumigatus lung infections in vivo, uptake by the liver 
was also evident. We hypothesized that this was due 
to non-specific hepatic clearance of the radiolabeled 
antibody or transchelation of 64Cu upon unstable 
binding to its chelator as seen by others [24] and that 
liver uptake might be reduced by using the chelators 
DOTAGA or NODAGA in place of DOTA. In vivo 
biodistribution of the tracers [64Cu]NODAGA-ET901, 
[64Cu]DOTAGA-mJF5, [64Cu]NODAGA-mJF5 and 
[64Cu]NODAGA-hJF5 showed no significant 
difference in uptake between DOTAGA- and 
NODAGA-labeled JF5 antibodies in the liver 3 h, 24 h 
and 48 h p.i. (Fig. S6). However, [64Cu]DOTAGA-mJF5 
was highest in the liver of A. fumigatus infected 
animals 48 h p.i. with 12.9 ± 4.1 %ID/cc compared to 
[64Cu]NODAGA-mJF5 (7.3 ± 1.8 %ID/cc) and 
[64Cu]NODAGA-hJF5 (10.0 ± 0.8 %ID/cc). [64Cu]Cl2 
was injected for control purposes to preclude 
unspecific perfusion effects of the antibody-based 
tracer and presented with significantly higher uptake 
in the liver of A. fumigatus infected animals with 26.0 ± 
5.0 %ID/cc (3 h p.i.) compared to all other 
investigated groups. A. fumigatus infected mice 
presented with higher liver uptake of [64Cu]Cl2 and 
[64Cu]DOTAGA-mJF5 compared to the radiolabeled 
ET901 isotype control antibody and 
[64Cu]NODAGA-labeled JF5-based tracers (Fig. S6, 
Table 1).  
Discussion  
Early detection of invasive pulmonary 
aspergillosis (IPA) and treatment with appropriate 
antifungal drugs is critical to patient survival, but 
clinical diagnosis remains extremely difficult. 
Mycological culture from sterile biopsy, still regarded 
as the gold standard for IPA diagnosis, is limited by 
poor sensitivity and lengthy turnaround time, and 
assays used to detect biomarkers of infection 
(Aspergillus cell wall galactomannan and ‘pan-fungal’ 
β-D-glucan) in serum or bronchoalveolar lavage fluid 
(BALf), lack either sensitivity or specificity and, in the 
case of BALf, involve invasive procedures [9]. While a 
point-of-care lateral-flow assay for IPA diagnosis has 
been developed [12] and has the potential to increase 
the speed and accuracy of detection [4], the present 
limitations of IPA diagnostics has led to the empirical 
or ‘fever-driven’ use of antifungals, resulting in the 
sometimes unnecessary exposure of patients to toxic 
drugs, increased likelihood of severe drug-drug 
interactions, inflated treatment costs, and contributes 
to the emergence of resistance to mould-active 
triazoles in Aspergillus species. Empirical antifungal 
therapy also reduces the sensitivity of culture-based 
and non-culture-based diagnostic tests, which are 
needed to establish a conclusive diagnosis, to 
determine drug sensitivities of cultured pathogens, 
and to monitor responsiveness to treatments. 
 Anti-fungal therapy guided by 
diagnostic-driven approaches has been shown to be 
more effective than empirical treatment both in terms 
of cost and improved patient outcomes [9]. Such a 
diagnostic-driven approach to IPA treatment typically 
relies on radiographic imaging, especially computed 
tomography (CT), coupled with frequent testing for 
fungal biomarkers. A chest CT that reveals dense, 
well-delineated, infiltrates in the lung with or without 
a ‘halo sign’ in a patient with prolonged neutropenia 
and persistent or recurrent fever of unknown cause 
that is unresponsive to empirical antibacterial agents, 
is suggestive of IPA. However, these radiological 
signs are not pathognomonic since other mould 
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pathogens and bacterial pathogens capable of 
angio-invasion can produce a similar appearance in 
CT.  
Despite the limited specificity of standard CT for 
diagnosing IPA, or invasive fungal diseases (IFDs) in 
general, CT remains a trigger for commencing 
antifungal treatment in many hematology units. 
Attempts have been made to improve the accuracy of 
radiographic imaging for early diagnosis and 
monitoring of IPA, by combining measures of 
metabolic activity with positron emission tomography 
(PET), but these methods fail to discriminate between 
infection and non-infectious pathologies [10, 11]. A 
number of studies have suggested that 
[18F]fluorodeoxyglucose ([18F]FDG), a diagnostic 
tracer that accumulates in metabolically-active 
inflammatory and cancer cells, might be useful for 
differentiating between non-invasive and invasive 
aspergillosis and for monitoring IPA response to 
antifungal treatment [25]. However, a recent study 
conducted by our group, using PET and magnetic 
resonance imaging (PET/MRI) to detect A. fumigatus 
lung infections in vivo, showed that increased uptake 
of [18F]FDG in IPA was indistinguishable from the 
uptake seen during inflammatory reactions due to 
sterile triggers, or during infections by the bacterial 
pathogens Streptococcus pneumonia and Yersinia 
enterocolitica [8]. 
Improvements in the accuracy of PET-based 
imaging for infectious disease diagnosis have been 
met through the use of small molecules such as 
18F-labelled maltohexaose, fluorodeoxysorbitol, or 
ciprofloxacin, but the majority of these target bacterial 
infections [26]. Few tracers have been developed that 
specifically target IFDs, but some success has been 
achieved in visualizing IPA by combining 
microPET/CT with 68Ga-radiolabeled siderophores 
[27]. The use of monoclonal antibodies in the 
molecular imaging of IFDs has yet to be exploited, but 
we recently demonstrated the enormous potential of 
antibody-guided PET/MRI (immunoPET/MRI) for 
accurate diagnosis of IPA [8]. Our diagnostic probe, 
which allows non-invasive detection of A. fumigatus 
lung infections in vivo, employs the 
Aspergillus-specific mouse monoclonal antibody 
(mAb) mJF5. The mAb, which forms the basis of the 
Aspergillus LFA [4, 12], binds to a diagnostic 
mannoprotein antigen which is secreted during active 
growth of the pathogen only, and so is able to 
discriminate between inactive spores present in 
inhaled air and invasive hyphae that infect the lung of 
the neutropenic host. When coupled to [64Cu]DOTA, 
the long half-life of the [64Cu]DOTA-mJF5 tracer 
enables sequential imaging of IPA and so represents 
an ideal candidate for repeated imaging of patients 
following a single injection of the radioactive tracer. 
Furthermore, the hyphal-specific nature of the 
immuno-PET tracer may prove useful in monitoring 
infection in response to antifungal treatment.  
In this study, we have engineered the JF5 
antibody for use in humans by grafting of the 
complementarity determining regions of the mouse 
antibody into a human IgG1 antibody framework, to 
make a humanised JF5 antibody (hJF5). The 
pre-clinical studies conducted here using the 
64Cu-labeled hJF5 antibody in a neutropenic mouse 
model of IPA, have demonstrated improved uptake of 
the hJF5-based PET tracer in infected lung tissues 
compared to its murine counterpart. Increased 
binding of hJF5 and hJF5-NODAGA compared to 
mJF5 and mJF5-NODAGA, although not significant, 
was further demonstrated in vitro during ELISA tests 
with the purified mannoprotein antigen. The reasons 
for this increased affinity have yet to be established, 
but there is increasing evidence to suggest that 
exchanging murine and human immunoglobulin 
constant chains can have profound effects on the 
kinetics of antigen binding [28, 29]. Furthermore, 
while there is extensive anecdotal and unpublished 
evidence that attempts to generate humanised mAbs 
based on mouse V regions have failed to produce 
useful antibodies because of loss of affinity and 
specificity, our work shows successful generation of a 
higher affinity (humanised) antibody for in vivo 
imaging of IPA, and retention of specificity for the 
invasive hyphal growth phase of the pathogen. 
In our previous work [8], specific uptake of 
[64Cu]DOTA-mJF5 was shown in the lungs of A. 
fumigatus infected animals compared to PBS-treated 
control mice, but was also accompanied by high liver 
uptake in all animals. Uptake of [64Cu]DOTA-mJF5 
was increased in the livers of A. fumigatus infected 
animals (27.35 ± 2.72 %ID/g), and in PBS control mice 
(15.77 ± 3.05 %ID/g) in ex vivo biodistribution studies 
at 48 h p.i. [8]. Possible reasons for this were 
considered to be (1) non-specific hepatic clearance of 
the radiolabeled antibody, (2) binding of the tracer to 
mannoprotein in the liver following release of soluble 
antigen from infection foci in the lungs, and (3) 
trans-chelation of 64Cu to abundant liver proteins due 
to insufficiently strong binding of 64Cu to its chelator. 
The chelator DOTA is known to have poor in vivo 
stability, which results in loss of the radio-metal and 
its non-specific accumulation in non-target tissue. In 
recent years, alternative chelators such as DOTAGA 
and NODAGA have been reported which have 
increased in vivo stability [30, 31, 32]. Here, we found 
that NODAGA provided the lowest liver uptake of 
both the mJF5 and hJF5-labeled antibodies in A. 
fumigatus infected animals (9.6 ± 3.0 %ID/g and 9.6 ± 
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1.2 %ID/g, respectively), and in PBS-treated mice (5.5 
± 0.7 %ID/g and 7.5 ± 1.1 %ID/g, respectively), while 
maintaining the highest level of uptake in the infected 
lungs (31.6 ± 5.1 %ID/g and 33.8 ± 4.0 %ID/g, 
respectively). Serum stability showed no signs of 
proteolytic degradation, protein aggregation or 
transchelation of 64Cu to serum proteins. Thus, the 
improved biodistribution of the DOTAGA- and 
NODAGA-labeled antibodies is consistent with the 
improved in vivo stability of these chelators, resulting 
in decreased uptake of radiolabeled 
immuno-conjugates in the liver [30, 31, 32]. 
In conclusion, we have shown that the 
humanised JF5 antibody tracer has enhanced 
diagnostic performance for non-invasive imaging of 
A. fumigatus lung infections in vivo compared to its 
mouse counterpart. It is essentially translatable to the 
clinical setting since the mAb targets a signature 
molecule of Aspergillus infection that has been 
clinically authenticated for IPA diagnosis in humans 
based on LFA tests of serum and bronchoalveolar 
lavage fluids [4, 12]. Furthermore, we have shown 
that the mJF5 and hJF5 antibodies bind to the 
antigenic determinant β1,5-galactofuranose (Galf) 
present in the target mannoprotein antigen. The 
absence of the epitope Galf in mammalian 
carbohydrates [17], coupled with the improved 
imaging capabilities of the hJF5 antibody, means that 
the [64Cu]NODAGA-hJF5 tracer should not bind to 
human structures non-specifically. This is very 
promising for the specificity of the imaging approach. 
At the same time, it reduces substantially the 
likelihood of adverse events when applying this 
antibody to humans. The hJF5 antibody therefore 
represents an excellent candidate for clinical studies 
of radiological IPA detection. 
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Supplementary figures and table. 
http://www.thno.org/v07p3398s1.pdf  
Acknowledgements 
We are grateful to Walter Ehrlichmann for the 
64Cu production and Maren Harant, Sandro Aidone 
and Ramona Stumm for expert technical assistance. 
This work was supported by the European Union 
Seventh Framework Programme FP7/2007-2013 
under Grant 602820, the Deutsche 
Forschungsgemeinschaft (Grant WI3777/1-2 to SW), 
and the Werner Siemens Foundation. We thank Sven 
Krappman for use of the A. fumigatustdTomato strain, 
and acknowledge the Imaging Centre Essen (IMCES) 
for assistance with optical imaging of lungs. 
Authors’ Contributions 
Conception and design: G.D., A.-M.R., M.H., 
F.B., M.G., M.J., R.S., B.J.P., S.W., and C.R.T. 
Development of methodology: G.D., A.-M.R., A.M., 
P.R.S., C.S., D.S.-S., M.H., J.W., J.F., A.D., F.B., F.D., 
M.G., L.S.R., M.J., R.S., B.J.P., S.W., and C.R.T. 
Statistical analysis: A.-M.R., M.E., S.W. and C.R.T. 
Writing of the manuscript: G.D., A.-M.R., A.M., P.R.S., 
M.H., J.F., F.B., M.G., M.E. M.J., R.S., B.J.P., S.W., and 
C.R.T. 
Competing Interests 
B.J.P. receives grant/research support from: 
Bayer Healthcare, Boehringer-Ingelheim, and 
Siemens; however, none of the grants are directly 
related to this work. C.R.T. is director of ISCA 
Diagnostics Ltd. 
References 
1. [Internet] WHO: Geneva, Switzerland. World Health Statistics 2014. 
http://www.who.int/mediacentre/news/releases/2014/world-health-statist
ics-2014/en/  
2. Brown GD, Denning DW, Gow NAR, et al. Hidden killers: human fungal 
infections. Sci Transl Med. 2012; 4 (165): 165rv13.  
3. [Internet] HM Government: London, United Kingdom. Review on 
antimicrobial resistance. Tackling drug-resistant infections globally: final 
report and recommendations. 2016 https://amr-review.org/ 
4. Prattes J, Prueller F, Koidl C, et al. Novel tests for diagnosis of invasive 
pulmonary aspergillosis in patients with underlying respiratory diseases. Am 
J Resp Crit Care Med. 2014; 190 (8): 922-929. 
5. Pichler BJ, Kolb A, Nägele T, et al. PET/MRI: paving the way for the next 
generation of clinical multimodality imaging applications. J Nucl Med. 2010; 
51 (3): 333-336. 
6. Santangelo PJ, Rogers KA, Zurla C, et al. Whole-body immunoPET reveals 
active SIV dynamics in viremic and antiteroviral therapy-treated macaques. 
Nat Methods. 2015; 12 (5): 427-432. 
7. Wiehr S, Warnke P, Rolle A-M, et al. New pathogen-specific immunoPET/MR 
tracer for molecular imaging of a systemic bacterial infection. Oncotarget. 
2016; 7: 10990-11001. 
8. Rolle A-M, Hasenberg M, Thornton CR, et al. ImmunoPET/MR imaging 
allows specific detection of Aspergillus fumigatus lung infection in vivo. Proc 
Nat Acad Sci USA. 2016; 113 (8): 1026-1033. 
9. Segal BM. Aspergillosis. New Engl J Med. 2009; 360: 1870-1884. 
10. Glaudemans AW, Quintero AM, Signore A. PET/MRI in infectious and 
inflammatory diseases: will it be a useful improvement? Eur J Nucl Med Mol 
Imaging. 2012; 39 (5): 745-749. 
11. Glaudemans AW, Slart RH, van Dijl DM, et al. Molecular imaging of infectious 
and inflammatory diseases: a terra incognita. J Nucl Med. 2015; 56 (5): 659-661.  
12. Thornton CR. Development of an immunochromatographic lateral flow 
device for rapid serodiagnosis of invasive aspergillosis. Clin Vacc Immunol. 
2008; 15 (7): 1095-1105. 
13. Thornton CR. Breaking the mould – novel diagnostic and therapeutic 
strategies for invasive pulmonary aspergillosis in the immune deficient 
patient. Expert Rev Clin Immunol. 2014; 6 (10): 771-780. 
14. Komachi Y, Hatakeyama S, Motomatsu H, et al. gfsA encodes a novel 
galactofuranosyltransferase involved in biosynthesis of galactofuranose 
antigen of O-glycan in Aspergillus nidulans and Aspergillus fumigatus. Mol 
Microbiol. 2013; 90 (5): 1054-1073. 
15. Latgé JP. Galactofuranose containing molecules in Aspergillus fumigatus. Med 
Mycol. 2009; 47: S104-S109. 
16. Schmalhorst PS, Krappman S, Vervecken W, et al. Contribution of 
galactofuranose to the virulence of the opportunistic pathogen Aspergillus 
fumigatus. Euk Cell. 2008; 7 (8): 1268-1277. 
17. Tefsen B, Ram AFJ, van Die I, et al. Galactofuranose in eukaryotes: aspects of 
biosynthesis and functional impact. Glycobiology 2012; 22 (4): 456-469. 
18. Catlett NL, Lee BE, Yoder OC, et al. Split-marker recombination for efficient 
targeted deletion of fungal genes. Fungal Genet Newsl. 2003; 50: 9-11. 
19. Kershaw MJ, Talbot NJ. Genome-wide functional analysis reveals that 
infection-related fungal autophagy is necessary for rice blast disease. Proc Natl 
Acad Sci USA. 2009; 106: 15967-15972. 
20. Thornton CR, Ryder LS, Le Cocq K, et al. Identifying the emerging human 
pathogen Scedosporium prolificans by using a species-specific monoclonal 
antibody that binds to the melanin biosynthetic enzyme 
tetrahydroxynaphthalene reductase. Env Microbiol. 2015; 17: 1023-1048.  
 Theranostics 2017, Vol. 7, Issue 14 
 
 
http://www.thno.org 
3414 
21. Thornton CR. Immunological methods for fungi. In Molecular and Cellular 
Biology of Filamentous Fungi, A Practical Approach. Talbot, N.J. (ed.). Oxford, UK: 
University Press, 2001; pp. 227-257. 
22. Laemmli UK. Cleavage of structural proteins during assembly of the head of 
bacteriophage T4. Nature. 1970; 227: 680-695. 
23. Wehrl HF, Hossain M, Lankes K, et al. Simultaneous PET-MRI brain function 
in activated and resting state on metabolic, hemodynamic and multiple 
temporal scales. Nat Med. 2013; 19: 1184-1189. 
24. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 
2008; 14 (3): 191-197. 
25. Hot A, Maunoury C, Poiree S, et al. Diagnostic contribution of positron 
emission tomography with [18F]fluorodeoxyglucose for invasive fungal 
infections. Clin Microbiol Infect. 2011; 17 (3): 409-417. 
26. Van Oosten M, Hahn M, Crane LMA, et al. Targeted imaging of bacterial 
infections: advances, hurdles and hopes. FEMS Microbiol Rev. 2015; 39: 
892-916. 
27. Petrik M, Haas H, Dobrozemsky G, et al. 68Ga-siderophores for PET imaging 
of invasive pulmonary aspergillosis: Proof of principle. J Nucl Med. 2010; 51 
(4): 639-645. 
28. Dillon MJ, Loban RA, Reed DE, et al. Contribution of murine IgG Fc regions to 
antibody binding to the capsule of Burkolderia pseudomallei. Virulence. 2016; 7 
(6): 691-701. 
29. Torres M, Fernandez-Fuentes N, Fiser A, et al. Exchanging murine and human 
immunoglobulin constant chains affects the kinetics and thermodynamics of 
antigen binding and chimeric antibody autoreactivity. PLoS ONE. 2007; 12: 
e1310. 
30. Boswell CA, Sun XK, Niu WJ, et al. Comparative in vivo stability of 
copper-64-labeled cross-bridged and conventional tetraazamacrocyclic 
complexes. J Med Chem. 2004; 47: 1465-1474. 
31. Ghosh SC, Pinkston KL, Robinson H, et al. Comparison of DOTA and 
NODAGA as chelators for 64Cu-labeled immunoconjugates. Nucl Med Biol. 
2015; 42 (2): 177-183.  
32. Westerlund K, Honarvar H, Norrtsrom E, et al. Increasing the net negative 
charge by replacement of DOTA chelator with DOTAGA improves the 
biodistribution of radiolabeled second-generation synthetic affibody 
molecules. Mol Pharmaceutics. 2016; 13 (5): 1668-1678. 
